martes, 29 de octubre de 2013

WHO Pharmaceuticals Newsletter (No.5, 2013)

Contenidos
Regulatory Matters
Acetaminophen ............................................................................................ 4
Caffeine for apnoea of prematurity ................................................................. 4
Calcitonin medicines ..................................................................................... 4
Codeine ...................................................................................................... 5
Diclofenac ................................................................................................... 6
Ergot derivatives .......................................................................................... 6
Filgrastim and pegfilgrastim ........................................................................... 7
Flupirtine-containing medicines ...................................................................... 7
Intravenous iron-containing medicines ............................................................ 8
Ketoconazole, oral ........................................................................................ 8
Mefloquine Hydrochloride .............................................................................. 9
Meprobamate ............................................................................................. 10
Metoclopramide .......................................................................................... 10
Ondansetron for intravenous use .............................................................. 11
Retigabine.................................................................................................... 11
Sunitinib malate .......................................................................................... 11

Safety of medicines
Nitrofurantoin ............................................................................................ 13
Panitumumab ............................................................................................. 13
Pazopanib hydrochloride............................................................................. 13
Rituximab .................................................................................................. 14
Vemurafenib............................................................................................... 14

Signal
Mirtazapine and Rhabdomyolysis ................................................................ 15
Roflumilast and Melaena .............................................................................. 18
Tapentadol and Delusion .............................................................................. 23

disponible en
en http://bit.ly/1aCrU8S